Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
Baroncelli S, Villani P, Galluzzo CM, Cavalli A, Volpe A, Francisci D, Vivarelli A, Sozio F, Tedeschi S, Cirioni O, Sighinolfi L, Cusato M, Pirillo MF, Weimer LE, Fragola V, Parruti G, Regazzi M, Floridia M. Baroncelli S, et al. Among authors: galluzzo cm. Ther Drug Monit. 2013 Dec;35(6):785-90. doi: 10.1097/FTD.0b013e31829ad690. Ther Drug Monit. 2013. PMID: 24061444
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.
Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte Ad, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers. Palmisano L, et al. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47. J Acquir Immune Defic Syndr. 2007. PMID: 17972364 Clinical Trial.
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M. Baroncelli S, et al. Among authors: galluzzo cm. Ther Drug Monit. 2008 Oct;30(5):604-10. doi: 10.1097/FTD.0b013e3181867a6e. Ther Drug Monit. 2008. PMID: 18728627
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group. Baroncelli S, et al. Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6. Ann Pharmacother. 2010. PMID: 20371753 Clinical Trial.
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
Pirillo M, Palmisano L, Pellegrini M, Galluzzo C, Weimer L, Bucciardini R, Fragola V, Andreotti M, Marchei E, Pichini S, Vella S, Giuliano M. Pirillo M, et al. AIDS Res Hum Retroviruses. 2010 May;26(5):541-5. doi: 10.1089/aid.2009.0116. AIDS Res Hum Retroviruses. 2010. PMID: 20455761 Clinical Trial.
99 results